Chronic Gout
6
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Sel212 Lowdose
Research Leaders
7 sponsors active, led by Swedish Orphan Biovitrum
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
83%
5 trials in Phase 3/4
100%
5 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (6)
A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
Rasburicase Treatment in Chronic Gouty Arthritis
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
Research Network
Common Treatments
- Sel212 Lowdose2
- Sel212 Highdose2
- Pegloticase2
- Rasburicase1
- Allopurinol1
Active Sponsors
- Swedish Orphan Biovitrum2
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
- Selecta Biosciences, Inc.1
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1
- Amgen1
Top Investigators
University of California, San Francisco
Horizon Therapeutics
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Related Conditions
- Hyperuricemia1
- Uncontrolled Gout1